NYSE: CRICarters Inc Stock
$35.76+1.05 (+3.03%)
Updated Mar 31, 2026
CRI Price
$35.76
Fair Value Price
N/A
Market Cap
$1.30B
52 Week Low
$23.38
52 Week High
$44.44
P/E
14.13x
P/B
1.41x
P/S
0.42x
PEG
0.86x
Dividend Yield
2.8%
Revenue
$2.90B
Earnings
$91.80M
Gross Margin
45.4%
Operating Margin
5.11%
Profit Margin
3.2%
Debt to Equity
1.77
Operating Cash Flow
$122M
Beta
1.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CRI Overview
Carter's, Inc. sells children's apparel through its Carter's and OshKosh B'gosh retail stores, its website, and department stores. Carter's was founded in 1865 and is headquartered in Atlanta, GA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Apparel
Industry Rating
A
CRI
Ranked#16 of 26
Ranked#16 of 26
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.70 | A | |
| $46.36 | A | |
| $11.24 | B |
Be the first to know about important CRI news, forecast changes, insider trades & much more!
CRI News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRI scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRI ($35.76) is trading above its intrinsic value of $28.12, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRI is good value based on its earnings relative to its share price (14.13x), compared to the US market average (30.95x)
P/E vs Market Valuation
CRI is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CRI due diligence checks available for Premium users.
Valuation
CRI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
14.13x
Industry
29.19x
Market
30.95x
CRI is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CRI is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CRI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.41x
Industry
8.12x
CRI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRI price to earnings growth (PEG)
For valuing profitable companies with growth potential
CRI is good value based... subscribe to Premium to read more.
PEG Value Valuation
CRI's financial health
Profit margin
Revenue
$925.5M
Net Income
$64.2M
Profit Margin
6.9%
CRI's Earnings (EBIT) of $148.06M... subscribe to Premium to read more.
Interest Coverage Financials
CRI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.6B
Liabilities
$1.6B
Debt to equity
1.77
CRI's short-term assets ($1.27B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRI's short-term assets ($1.27B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$258.6M
Investing
-$11.0M
Financing
$54.2M
CRI's operating cash flow ($122.33M)... subscribe to Premium to read more.
Debt Coverage Financials
CRI vs Apparel Stocks
Carters Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.